Usage Examples
- The umbrella opens a fifth arm once the biomarker assay is validated.
- One disease, four targeted agents by mutation, so it is an umbrella and not a basket.
- Each umbrella arm needs its own protocol amendment when the dosing schedule changes.
What is Umbrella Trial?
An umbrella trial is a master protocol design that enrols a single disease and assigns participants to different investigational therapies by molecular subtype, running those arms as sub-studies under one governing framework.
Umbrella trials exist because a single disease is often several diseases at the molecular level. Running a separate trial for each targeted agent means duplicating screening, infrastructure, and control groups across studies that all recruit from the same population. An umbrella trial screens once, then routes each participant to the arm matching their tumour or disease biology.
An umbrella trial covers one disease population and multiple investigational therapies assigned by molecular subtype, governed by a master protocol with sub-studies beneath it. Its scope excludes designs where the therapy is fixed and the disease varies, which is a basket trial. The umbrella label describes enrolment and allocation logic only; it says nothing about the trial's phase or whether its evidence is confirmatory.
Umbrella trials in practice depend on a screening and biomarker assay pipeline that can assign participants reliably, and on a governing document that lets arms open and close without renegotiating the whole study. Each planned study still requires its own protocol, and material changes to an arm still move through protocol amendment.
Not to be confused with
- Basket trial
- a basket trial holds the therapy constant and varies the disease; an umbrella trial holds the disease constant and varies the therapy across molecularly defined arms. Identical master-protocol machinery, opposite axis of variation.
- Master protocol
- the master protocol is the governing document that permits several sub-studies under one framework. An umbrella trial is one design built with that document; basket and platform trials are others.
- Adaptive trial design
- adaptive refers to prospectively planned modifications driven by accumulating data. Umbrella refers to how participants are allocated across arms. A trial can be either, both, or neither.
- Phase 3
- a phase designation describes the evidentiary stage. Umbrella describes allocation logic. Calling a study an umbrella tells you nothing about whether its evidence is intended to be confirmatory.
No regulation governs umbrella trials by name; the IND requirements that apply to any investigation apply to each sub-study.
What you must do
- 1Include a protocol for each planned study in the IND21 CFR 312.23(a)(6)
- 2Submit a protocol amendment for any change to a Phase 2 or 3 protocol that significantly affects subject safety, the scope of the investigation, or the scientific quality of the study, which covers adding or materially altering an arm21 CFR 312.30(b)(1)
- 3Before making such a change, submit it to FDA for review and obtain approval from the IRB responsible for the study21 CFR 312.30(b)(2)(i)
- 4Follow the current FDA recommendations on design, analysis, and regulatory submissions for trials conducted under a master protocol91 FR 37991
Common mistakes
Using umbrella and basket interchangeably
they are opposite designs. The distinction determines what the control arm means, how the analysis is powered, and what an efficacy signal in one arm implies for the others. Getting the label wrong in a protocol synopsis signals to a reviewer that the design rationale was not thought through.
Treating the master protocol as removing amendment obligations
the framework reduces duplicated startup work, not the requirement in 21 CFR 312.30 to submit amendments for changes that significantly affect safety, scope, or scientific quality. Opening an arm without the amendment and IRB approval that 312.30(b)(2)(i) requires is a compliance finding, not an efficiency.
Relying on the 2023 draft guidance
FDA revised and replaced the December 22, 2023 draft with a new draft published June 24, 2026 at 91 FR 37991. Design and submission plans written against the superseded version may not reflect the current recommendations, and both documents remain draft rather than binding.
When This Matters
- The umbrella opens a fifth arm once the biomarker assay is validated.
- One disease, four targeted agents by mutation, so it is an umbrella and not a basket.
- Each umbrella arm needs its own protocol amendment when the dosing schedule changes.
Frequently Asked Questions
The axis of variation. An umbrella trial holds the disease constant and varies the therapy across molecularly defined arms. A basket trial holds the therapy constant and varies the disease. Both use the same master protocol machinery, so the distinction is what is fixed and what is compared.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
